MYRIAD myChoice® CDx

The most comprehensive tumor test to determine HRD status

myriad®

Homologous recombination deficiency (HRD) is present in approximately 48%[1] of ovarian cancer tumors



Some **CAUSES** of HRD are well established while others remain unknown[2,3,4]



1. Moore et. al, Lancet Oncol 2019
2. Bonadio et al. Clinics 2018
3. Watkins et al. Breast Ca Res 2014
4. Panagiotis et al. Cancer Discov 2015

There are limitations to determining HRD status when evaluating each cause individually

HRD resulting from epigenetic events such as *BRCA1* promotor methylation will be missed with a gene sequencing approach[1,2]

HR pathway gene mutations other than *BRCA1* and *BRCA2* are rare and it is unclear if they are connected to HRD[3,4]

There is a distinct genomic **EFFECT** associated with HRD[5]



LOH
Loss of Heterozygosity

TAI
Telomeric Allelic Imbalance

LST
Large-Scale State Transitions

Evaluating **LOH, TAI** and **LST** allows for the assessment of HRD regardless of the specific cause[5]

1. Timms et al. Br Ca Res 2014
2. Baldwin et al. Cancer Research 2000
3. Norquist et al. JAMA Oncol. 2016
4. The Cancer Genome Atlas. Nature 2011
5. Watkins et al. Breast Ca Res 2014

myChoice CDx is the only FDA-approved tumor test that determines HRD status using two individual methods

1 ***BRCA1* & *BRCA2* Status** | **Sequence Variants** + **Large Rearrangements**

- Detection and classification of sequence variants and large rearrangements
- Identification of somatic and germline variants present in the tumor

2 **Genomic Instability Status** | **LOH** Loss of Heterozygosity + **TAI** Telomeric Allelic Imbalance + **LST** Large-Scale State Transitions

- Comprehensive assessment of LOH, TAI and LST across the entire genome

myChoice CDx identifies more ovarian cancer tumors with HRD than other testing methods



1. Moore et. al, Lancet Oncol 2019

myChoice CDx delivers affordable results in 14 days or less

Provider completes the test request form (TRF)

Myriad receives the TRF and sends sample preparation kit to the pathology lab

Tumor sample* arrives at Myriad and myChoice CDx testing is performed

Results are sent to the ordering provider and pathologist

Tumor sample returned to the pathology lab immediately after result reporting

*myChoice CDx is run on formalin-fixed paraffin-embedded (FFPE) ovarian tumor tissue

If you have questions about the test or ordering process, Myriad experts are available to assist you:


Customer Service: myChoiceCDx@myriad.com


Clinical Support: hrdhelpmed@myriad.com


877-283-6709

myChoice CDx can inform late-line treatment decisions with ZEJULA® (niraparib)

myChoice CDx Intended Use

Myriad myChoice® CDx is a next generation sequencing-based *in vitro* diagnostic test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the *BRCA1* and *BRCA2* genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status for treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling.

Table 1: Companion diagnostic indications

Tumor Type	Biomarker	Therapy
Ovarian Cancer	Myriad HRD (defined as deleterious or suspected deleterious mutations in *BRCA1* and *BRCA2* genes and/or positive Genomic Instability Score)	ZEJULA® (niraparib)

This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, Inc., a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108.

The indication for ZEJULA[1] for which Myriad myChoice CDx is an FDA-approved companion diagnostic is a follows: the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:

- a deleterious or suspected deleterious BRCA mutation, or
- genomic instability and who have progressed more than six month after response to last platinum-based chemotherapy

Select patients based on FDA-approved companion diagnostic

1. ZEJULA (niraparib) [package insert]. Waltham, MA: TESARO, Inc.; October 2019

* A companion diagnostic is not a requirement for all uses of Zejula. Questions regarding Zejula should be directed to its manufacturer, GSK.